Metabolic Diseases: Type 2 Diabetes

Over the past decades the incidence of diabetes has progressively increased. According to the American Diabetes Association (ADA), diabetes affects more than 20 million people in the USA alone. Diabetes is associated with increased risk of a number of serious complications.

Prous Institute's research efforts are focused on developing novel, more effective and safer therapies for type 2 diabetes. Our potent SGLT2 inhibitors work in a completely different way to any previous type 2 diabetes therapeutics.

Compound      
Target / Action Status                                                    
 JRP 493
SGLT2  / Inhibitor        
Preclinical, Patent application submitted
 

Type 2 diabetes is characterized as a proinflammatory and procoagulant condition. The high incidence of cardiovascular ischemic events in patients with type 2 diabetes is explained by the development of atherothrombotic lesions. Compound JRP 493 has been proven to control glycemia and to have moderate platelet antiaggregatory activity.